title: Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
authors.affiliation: SBU Therapeutics, Schering AG Berlin, Germany. Reinhard.Horowski@Schering.de
authors.forename: R
authors.initials: R
authors.lastname: Horowski
authors.forename: C S
authors.initials: CS
authors.lastname: Stürzebecher
authors.forename: J F
authors.initials: JF
authors.lastname: Kapp
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000906:Antibodies / Q000032:analysis / Q000276:immunology*; D000917:Antibody Formation; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D009500:Neutralization Tests; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a